Pfizer To Pay $325M To End Neurontin Off-Label Suit
Pfizer Inc. and Warner-Lambert Co. LLC have agreed to pay $325 million to a class of third-party payers who bought the drug Neurontin to settle allegations that they fraudulently marketed the...To view the full article, register now.
Already a subscriber? Click here to view full article